A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared manufacturing site.
Almirall licenses bispecific platform in $210m EpimAb deal (BioProcess International)
EpimAb Biotherapeutics has out-licensed the rights for its Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform technology to Barcelona’s Almirall, a dermatology company.
Almirall will gain global ownership of up to three bispecific antibodies it discovers and develops using the platform. EpimAb will receive as much as $210 million in milestones contingent upon launch and commercial success of the products, plus royalties.
Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona (CataloniaBio & HealthTech)
Almirall, a global biopharmaceutical company focused on medical dermatology, today announced an agreement with Centrient Pharmaceuticals, a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals,, to open its new dedicated innovation lab at Almirall’s R&D centre. Centrient’s new Innovation Laboratory will start operations in the first quarter of 2024.
Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain (Yahoo Finance)
Besins Healthcare, a global lead in Women’s and Men’s Reproductive Health, today unveiled its novel hormone production facility in Muel, situated near Zaragoza, Spain. This event represents a significant moment in European pharmaceutical history.
Spain headquartered, Insud Pharma Opens first of its kind Oligonucleotides Centre in Hyderabad, India (Company website)
Insud Pharma, a leading Spanish multinational pharmaceutical company, today inaugurated its state-of-the-art Oligonucleotides Centre at its campus in Chemo India Formulation Private Limited, a wholly-owned subsidiary of Insud Pharma.
This is the first-of-its-kind research and production center in India, focused on Oligonucleotides research and commercial production. It also ranks among the top 5 globally, alongside brand companies, with a focus on the US, EU, and numerous global markets. This facility has been inspected and approved by the US FDA, Spanish Health Agency, Drug Control General of India, and various international customers.
Esteve Quimica’s New Site Receives FDA Full Clearance To Commercialize Products In US (Pharmaceutical Online)
The acquisition of a new industrial site in Lliçà de Vall (Barcelona) early in 2022 increased Esteve Quimica’s active pharmaceutical ingredients production capacity by 20%.
The operation was an excellent opportunity to continue positioning Esteve Química as an international reference partner for the development and manufacture of active pharmaceuticals ingredients for innovator pharma companies around the world.
BCN Health Booster accelerator companies collect 51.8 million euros (Muy Pymes, in Spanish)
The first generation of companies that participated in the BCN Health Booster accelerator captured €51.8 million in public and private financing during the year 2022, the first year of its success in progress. This figure represents a 106% respect to the 49 M€ that was raised before being incorporated into this program, led by the Parque Científico de Barcelona (PCB) and the City of Barcelona, with the support of Barcelona Activa and the collaboration of Biocat.
ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists (Fierce Pharma)
Attendees for the European Society for Medical Oncology Congress 2023 arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitement of an industry conference that promised to showcase breakthroughs in breast, lung and prostate cancers.
It was a return, if you can call it that, to normal after several years of pandemic interruption. But this year seemed to go even bigger than ever before.
ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies (Company website)
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the granting, through a provisional resolution proposal, of two aids within the Spanish research plan 2021-2023 for public-private collaboration projects: the DICTIONIS Project with a budget of 951,000 euros (€) and the MODERN Project with a budget of €1,328,594. The plan is funded by the Spanish State Research Agency and the Ministry of Science and Innovation within the framework of the recovery, transformation and resilience plan financed by the European Union (NextGenerationEU).
